glp 1 agonist vs sglt2 inhibitor Recommendations for SGLT2i versus GLP-1 RA on the basis of kidney Combining GLP-1 Receptor Agonists and

Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies

Publication: Canadian Journal of Physiology and Pharmacology 18 November 2025 Abstract Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), exert a wide range of beneficial effects beyond glycemic control, largely mediated by their anti-inflammatory properties

That headline is doing a lot of work before the science catches up

Human studies indicate that the insulinotropic action of GIP is blunted in individuals with severe hyperglycemia, in contrast to the intact action of GLP-1

Investigation 79 (2), 616619